Pharming Group reports interim financial results for the first nine months of 2018
Financial updatesPharming Group N.V. presents its (unaudited) interim financial report for the first nine months and the third quarter ended 30 September 2018.
2018
Pharming reports positive data from first investigator-initiated study of rhC1-Inhibitor (RUCONEST®) in Contrast-induced Nephropathy
Clinical trialsPharming Group N.V. announced positive results from a Phase II investigator-initiated study of RUCONEST® (recombinant human C1 esterase inhibitor, or “rhC1INH”) in a double-blind, placebo-controlled clinical trial in patients at risk of nephropathy resulting from contrast-enhanced examinations.
Pharming Receives Complete Response Letter from FDA
Operational updatesPharming Group N.V. announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the supplemental Biologics License Application (sBLA) for RUCONEST® [C1 Esterase Inhibitor (recombinant)] to expand the current indication to include prophylaxis in patients with hereditary angioedema (HAE).
Pharming announces further issue of shares as employee options are exercised
Financial updatesPharming Group N.V. today announced that it has issued a total of 6,240,000 new shares following exercise of warrants representing a total of 6,240,000 shares.
Pharming Reports on Financial Results for the First Half of 2018
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the six months ended 30 June 2018.
Pharming announces Agenda for its Capital Markets Briefing to be held on 21 June 2018 in New York
Financial updatesPharming Group N.V. announces the agenda for its Capital Markets Briefing to be held from 08:00 to 10:30 EST/14:00-16:30 CET on 21 June 2018 in New York, NY, and through a live webcast.
Pharming Reports On Annual General Meeting Of Shareholders
Financial updatesPharming Group N.V. announces that at its Annual General Meeting of shareholders (AGM), held today, all proposals were approved.
Pharming Group Interim Report on Financial Results for the First Quarter 2018
Financial updatesPharming Group N.V. presents its (unaudited) financial report for the quarter ended 31 March 2018.
A global awareness day for a rare life-threatening condition: World HAEday, 16th May 2018
Other updatesOn May 16th Hereditary Angioedema (HAE) patient organizations from around the world, led by HAEi (The international HAE patient organisation), come together to support the global awareness day for Hereditary Angioedema; a rare life-threatening condition.
Pharming announces publication of 2017 Annual Report and invitation to Annual General Meeting of Shareholders
Financial updatesPharming Group N.V., the Dutch specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs, announces publication of its 2017 annual report and issues an invitation to its Annual General Meeting for all shareholders.